JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Cytek Biosciences Inc

Fermé

SecteurSoins de santé

4.42 -3.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.35

Max

4.55

Chiffres clés

By Trading Economics

Revenu

-39M

-44M

Ventes

9.8M

62M

Marge bénéficiaire

-70.929

Employés

702

EBITDA

4M

-263K

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+40.13% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

12M

573M

Ouverture précédente

7.91

Clôture précédente

4.42

Sentiment de l'Actualité

By Acuity

50%

50%

177 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Cytek Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 avr. 2026, 23:33 UTC

Actions en Tendance

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 avr. 2026, 23:24 UTC

Résultats

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 avr. 2026, 23:15 UTC

Principaux Événements d'Actualité

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 avr. 2026, 22:46 UTC

Résultats

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 avr. 2026, 22:37 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 avr. 2026, 22:15 UTC

Résultats
Principaux Événements d'Actualité

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 avr. 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 avr. 2026, 23:31 UTC

Résultats

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 avr. 2026, 23:31 UTC

Résultats

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 avr. 2026, 23:30 UTC

Résultats

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 avr. 2026, 23:30 UTC

Résultats

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 avr. 2026, 23:19 UTC

Market Talk
Résultats

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 avr. 2026, 23:09 UTC

Résultats

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 avr. 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 avr. 2026, 22:51 UTC

Résultats

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 avr. 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 avr. 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 avr. 2026, 22:40 UTC

Market Talk
Principaux Événements d'Actualité

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 avr. 2026, 22:32 UTC

Résultats

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 avr. 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 avr. 2026, 22:22 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 avr. 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 avr. 2026, 22:14 UTC

Résultats

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 avr. 2026, 22:14 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 avr. 2026, 22:07 UTC

Market Talk
Principaux Événements d'Actualité

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparaison

Variation de prix

Cytek Biosciences Inc prévision

Objectif de Prix

By TipRanks

40.13% hausse

Prévisions sur 12 Mois

Moyen 6.25 USD  40.13%

Haut 7.5 USD

Bas 5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

3.7 / 3.8Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

177 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat